Limits...
Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.

Lin YL, Gui SL, Guo H, Ma JG, Li WP - Med. Sci. Monit. (2015)

Bottom Line: PCDH17 methylation is significantly correlated with advanced stage, higher grade, and lymph node metastasis in ccRCC.PCDH17 methylation occurred more frequently and was associated with malignant clinicopathological characteristics and poor prognosis in ccRCC patients.Thus, PCDH17 methylation may be used as a novel biomarker to predict the prognosis of patients with ccRCC.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Affiliated Xuzhou Hospital of Jiangsu University (Xuzhou Cancer Hospital), Xuzhou, Jiangsu, China (mainland).

ABSTRACT

Background: Protocadherin17 (PCDH17) is a tumor suppressor gene, and is frequently silenced by promoter methylation in human cancers, including clear cell renal cell carcinoma (ccRCC). However, the clinical significance of PCDH17 methylation in ccRCC remains largely unclear. The aim of the present study was to investigate the methylation status of PCDH17 in ccRCC and its potential relevance to clinicopathological parameters and prognosis.

Material and methods: Methylation-specific PCR was used to examine the methylation status of PCDH17 in 191 ccRCC tumors and matched paired adjacent noncancerous tissues. Subsequently, the associations between PCDH17 methylation and clinicopathological parameters and prognosis of patients with ccRCC were analyzed.

Results: PCDH17 methylation occurred in 66.5% of ccRCC tumors, but in only 12.1% of adjacent noncancerous tissues. PCDH17 methylation is significantly correlated with advanced stage, higher grade, and lymph node metastasis in ccRCC. Moreover, it is an independent prognostic factor for progression-free survival and overall survival of patients with ccRCC.

Conclusions: PCDH17 methylation occurred more frequently and was associated with malignant clinicopathological characteristics and poor prognosis in ccRCC patients. Thus, PCDH17 methylation may be used as a novel biomarker to predict the prognosis of patients with ccRCC.

No MeSH data available.


Related in: MedlinePlus

Representative MSP results of PCDH17 methylation in patients with ccRCC. A: methylation control; B: unmethylation control; M: methylated; U: unmethylated; N: adjacent noncancerous tissues; T: ccRCC tissues. Cases9N, Case7T and Case9T exhibited methylated PCDH17. Case7N, Case8N and Case8T exhibited unmethylated PCDH17.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4588677&req=5

f1-medscimonit-21-2870: Representative MSP results of PCDH17 methylation in patients with ccRCC. A: methylation control; B: unmethylation control; M: methylated; U: unmethylated; N: adjacent noncancerous tissues; T: ccRCC tissues. Cases9N, Case7T and Case9T exhibited methylated PCDH17. Case7N, Case8N and Case8T exhibited unmethylated PCDH17.

Mentions: The methylation status of PCDH17 was detected in 191 ccRCC tumors and matched adjacent noncancerous tissues using MSP. PCDH17 methylation was detected in 127 (66.5%) ccRCC tumors, but PCDH17 methylation was only found in 23 (12.1%) adjacent noncancerous tissues. Representative MSP results are shown in Figure 1. The methylation rate of PCDH17 in ccRCC tumors is higher than that in adjacent noncancerous tissues, and the difference is statistically significant (P<0.0001, Table 2).


Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.

Lin YL, Gui SL, Guo H, Ma JG, Li WP - Med. Sci. Monit. (2015)

Representative MSP results of PCDH17 methylation in patients with ccRCC. A: methylation control; B: unmethylation control; M: methylated; U: unmethylated; N: adjacent noncancerous tissues; T: ccRCC tissues. Cases9N, Case7T and Case9T exhibited methylated PCDH17. Case7N, Case8N and Case8T exhibited unmethylated PCDH17.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4588677&req=5

f1-medscimonit-21-2870: Representative MSP results of PCDH17 methylation in patients with ccRCC. A: methylation control; B: unmethylation control; M: methylated; U: unmethylated; N: adjacent noncancerous tissues; T: ccRCC tissues. Cases9N, Case7T and Case9T exhibited methylated PCDH17. Case7N, Case8N and Case8T exhibited unmethylated PCDH17.
Mentions: The methylation status of PCDH17 was detected in 191 ccRCC tumors and matched adjacent noncancerous tissues using MSP. PCDH17 methylation was detected in 127 (66.5%) ccRCC tumors, but PCDH17 methylation was only found in 23 (12.1%) adjacent noncancerous tissues. Representative MSP results are shown in Figure 1. The methylation rate of PCDH17 in ccRCC tumors is higher than that in adjacent noncancerous tissues, and the difference is statistically significant (P<0.0001, Table 2).

Bottom Line: PCDH17 methylation is significantly correlated with advanced stage, higher grade, and lymph node metastasis in ccRCC.PCDH17 methylation occurred more frequently and was associated with malignant clinicopathological characteristics and poor prognosis in ccRCC patients.Thus, PCDH17 methylation may be used as a novel biomarker to predict the prognosis of patients with ccRCC.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Affiliated Xuzhou Hospital of Jiangsu University (Xuzhou Cancer Hospital), Xuzhou, Jiangsu, China (mainland).

ABSTRACT

Background: Protocadherin17 (PCDH17) is a tumor suppressor gene, and is frequently silenced by promoter methylation in human cancers, including clear cell renal cell carcinoma (ccRCC). However, the clinical significance of PCDH17 methylation in ccRCC remains largely unclear. The aim of the present study was to investigate the methylation status of PCDH17 in ccRCC and its potential relevance to clinicopathological parameters and prognosis.

Material and methods: Methylation-specific PCR was used to examine the methylation status of PCDH17 in 191 ccRCC tumors and matched paired adjacent noncancerous tissues. Subsequently, the associations between PCDH17 methylation and clinicopathological parameters and prognosis of patients with ccRCC were analyzed.

Results: PCDH17 methylation occurred in 66.5% of ccRCC tumors, but in only 12.1% of adjacent noncancerous tissues. PCDH17 methylation is significantly correlated with advanced stage, higher grade, and lymph node metastasis in ccRCC. Moreover, it is an independent prognostic factor for progression-free survival and overall survival of patients with ccRCC.

Conclusions: PCDH17 methylation occurred more frequently and was associated with malignant clinicopathological characteristics and poor prognosis in ccRCC patients. Thus, PCDH17 methylation may be used as a novel biomarker to predict the prognosis of patients with ccRCC.

No MeSH data available.


Related in: MedlinePlus